Table 3.
Characterization of the MIC value distribution of four AMPs against the clinical isolates.
| Species (no. Isolates) |
MIC50 a,b | MIC90 a,c | ||||||
|---|---|---|---|---|---|---|---|---|
| EtCec1 -OH d |
EtCec1 -NH2 e |
EtCec2 -OH d |
EtCec2 -NH2 e |
EtCec1 -OH d |
EtCec1 -NH2 e |
EtCec2 -OH d |
EtCec2 -NH2 e |
|
| Escherichia coli (26) | 8 | 4 | 32 | 16 | 32 | 8 | 128 | 32 |
| Enterobacter cloacae (23) | 8 | 4 | 128 | 32 | 128 | 16 | >128 | 128 |
| Klebsiella pneumoniae (21) | 32 | 4 | >128 | 128 | 128 | 16 | >128 | >128 |
| Salmonella enterica (10) | 32 | 16 | >128 | 128 | 32 | 16 | >128 | 128 |
| Acinetobacter baumannii (20) | 8 | 4 | 16 | 8 | 16 | 8 | 32 | 16 |
a MIC values were determined in cation-adjusted Mueller-Hinton broth (CAMB). b Concentration in µg/mL which inhibits the growth of 50% of the tested isolates. c Concentration in µg/mL which inhibits the growth of 90% of the tested isolates. d C-terminally carboxylated peptide form. e C-terminally amidated peptide form.